Hematologic Findings and Transfusion Therapy in Severe Pediatric Plasmodium Falciparum Malaria: Results from a Prospective Observational Study in Uganda

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 3041-3041
Author(s):  
Christine Cserti-Gazdewich ◽  
Aggrey Dhabangi ◽  
Charles Musoke ◽  
Nicolette Nabukeera-Barungi ◽  
Henry Ddungu ◽  
...  

Abstract Background: Plasmodium falciparum malaria is a leading global killer of children and cause for transfusion in endemic areas. Sequestration cytopenias and microvascular insufficiency are pathologic consequences of the acquired cytoadhesivity of P falciparum-infected red blood cells (iRBC). Parasite-derived surface knobs (PfEMP1) expressed on iRBC promote their binding to blood group ligands on non-infected blood cells and the microvascular endothelium. The purpose of the Cytoadherence in Pediatric Malaria Study (clinicaltrials.gov, NCT 00707200) is to study the association between malaria outcomes and host markers of cytoadhesion. Methods: This prospective observational study of children with malaria (age 6 m–12 y, HIV-neg) was launched in October 2007 at Mulago Hospital, Uganda. Patients with severe malaria syndromes, as defined by the WHO, were compared with uncomplicated malaria (UM) patients for presenting hematologic features and transfusion practices. Associations between severe malaria syndromes and mortality were also explored. Results: Over the study’s 1st 7 months, 785 patients were screened, 492 enrolled, and 44 excluded (40 malaria false positives, 4 HIV+). A total of 448 were analyzed (199 severe, 249 UM), including 16 deaths (severe malaria case fatality rate: 8%). Patients were 55% male/45% female. Severe malaria patients were significantly younger than those with UM (2.3 ± 1.9 y, 93% ≤ 5 y, vs 3.5 ± 2.7 y, 76% <5 y), p < 2×10−7. Hematologic features of the patients are summarized in Table 1, illustrating significantly greater derangements in the CBC of severe cases versus UM. In contrast, both groups had a similar sickle trait prevalence and level of parasitemia: Table 1: Hematologic Features in Uncomplicated Malaria (UM) vs Severe Malaria UM (n = 249) Severe (n = 199) signifinance WBC Count, × 10 9/L [mean ± sd] 8.1 ± 3.5 12.8 ± 8.1 p = 2.6 × 10−13 Hemoglobin, g/dL [mean ± sd] 9.3 ± 1.5 5.2 ± 2.1 p = 2.1 × 10−71 Severe Malarial Anemia [number, % ], Hb ≥ 5 g/dL 0 (0 %) 130 (65.3 %) χ2 = 226 Platelet Count, × 10 3/μL, [mean ± sd] 160,000 ± 103,000 129,000 ± 98,000 p =.0015 Severe Thrombocytopenia [n, %], Plt ≥ 50,000/μL 17 (6.8 %) 39 (19.6 %) χ2 = 15.3 Sickle Trait on Screen or History [n, %] 11/157 (7.0 %) 12/118 (10.2 %) χ2 =.51 (NS) Quantitative Parasitemia,/μL [median, range] 80,000 (7–10,638,000) 65,000 (60–2,593,000) p =.8 (NS) Hyperparasitemia [n, % ], Parasites ≥250,000/μL 42 (16.9 %) 44 (22.1 %) χ2 = 1.6 (NS) Among severe cases, severe malarial anemia (SMA) was the most common syndrome (n=130, 65%), followed by lactic acidosis (LA, n=93, 47%), respiratory distress (RD, n=91, 46%), hypoglycaemia (HG, n=22, 23%), cerebral malaria (CM, n=43, 22%), and hypoxia (HO, n=14, 7%). Among fatal cases, RD occurred most commonly (94%), followed by LA (75%), CM (56%), HG (42%), and SMA (only 31%). Overall, RBC transfusions were given to 78% of severe cases, and all but 1 of 130 SMA cases. Despite severe anemia, most received only 1 unit (1.2 ±.5 pediatric units/patient, range 1–3). 83% of transfusions were given for SMA and 10% for RD (without SMA). Significant delays or dose insufficiency of blood products occurred in 5.2% of recipients. ABO non-identical but compatible products were given 10.2% of the time. In unadjusted analysis of severe cases, associations between the hemolytic state of SMA and either hypoxia or respiratory distress (as possible signs of pulmonary hypertension) were not apparent (χ2=.01 and 2.2 respectively). LA was associated with SMA (χ2=4.7, p=.03), but not with the smaller subset of SMA patients with HO (χ2=.61, p=.43). The strongest association occurred between LA and RD (χ2=29.3, p<.0001), tying labored breathing to acidotic respiratory compensation. Conclusions: Hematologic abnormalities are seen across the entire spectrum of severe and uncomplicated pediatric P falciparum malaria in Uganda, and are most striking in the severe syndromes. Among patients with severe malaria, SMA is the most common feature, while severe thrombocytopenia occurs in up to 20%. SMA is not as predictive of death as either RD, LA, or CM. LA in turn occurs even in the absence of severe anemia and/or hypoxia, highlighting the potential contribution of microvascular ischemia from cytoadhesion. Cytoadhesion between infected red cells and host ligands is thus an appealing area of focus for studies of the pathogenesis of malaria morbidity and mortality in children.

Blood ◽  
2005 ◽  
Vol 106 (1) ◽  
pp. 368-371 ◽  
Author(s):  
Thomas N. Williams ◽  
Sammy Wambua ◽  
Sophie Uyoga ◽  
Alex Macharia ◽  
Jedidah K. Mwacharo ◽  
...  

Although the α+ thalassemias almost certainly confer protection against death from malaria, this has not been formally documented. We have conducted a study involving 655 case patients with rigorously defined severe malaria and 648 controls, frequency matched on area of residence and ethnic group. The prevalence of both heterozygous and homozygous α+ thalassemia was reduced in both case patients with severe malaria (adjusted odds ratios [ORs], 0.73 and 0.57; 95% confidence intervals [95% CIs], 0.57-0.94 and 0.40-0.81; P = .013 and P = .002, respectively, compared with controls) and among the subgroup of children who died after admission with severe malaria (OR, 0.60 and 0.37; 95% CI, 0.37-1.00 and 0.16-0.87; P = .05 and P = .02, respectively, compared with surviving case patients). The lowest ORs were seen for the forms of malaria associated with the highest mortality—coma and severe anemia complicated by deep, acidotic breathing. Our study supports the conclusion that both heterozygotes and homozygotes enjoy a selective advantage against death from Plasmodium falciparum malaria.


2021 ◽  
Vol 20 (1) ◽  
Author(s):  
Minh Cuong Duong ◽  
Oanh Kieu Nguyet Pham ◽  
Phong Thanh Nguyen ◽  
Van Vinh Chau Nguyen ◽  
Phu Hoan Nguyen

Abstract Background Drug-resistant falciparum malaria is an increasing public health burden. This study examined the magnitude of Plasmodium falciparum infection and the patterns and predictors of treatment failure in Vietnam. Methods Medical records of all 443 patients with malaria infection admitted to the Hospital for Tropical Diseases between January 2015 and December 2018 were used to extract information on demographics, risk factors, symptoms, laboratory tests, treatment, and outcome. Results More than half (59.8%, 265/443, CI 55.1–64.4%) of patients acquired Plasmodium falciparum infection of whom 21.9% (58/265, CI 17.1–27.4%) had severe malaria, while 7.2% (19/265, CI 4.6–10.9%) and 19.2% (51/265, CI 14.7–24.5%) developed early treatment failure (ETF) and late treatment failure (LTF) respectively. Among 58 patients with severe malaria, 14 (24.1%) acquired infection in regions where artemisinin resistance has been documented including Binh Phuoc (11 patients), Dak Nong (2 patients) and Gia Lai (1 patient). Under treatment with intravenous artesunate, the median (IQR) parasite half-life of 11 patients coming from Binh Phuoc was 3 h (2.3 to 8.3 h), two patients coming from Dak Nong was 2.8 and 5.7 h, and a patient coming from Gia Lai was 6.5 h. Most patients (98.5%, 261/265) recovered completely. Four patients with severe malaria died. Severe malaria was statistically associated with receiving treatment at previous hospitals (P < 0.001), hepatomegaly (P < 0.001) and number of inpatient days (P < 0.001). Having severe malaria was a predictor of ETF (AOR 6.96, CI 2.55–19.02, P < 0.001). No predictor of LTF was identified. Conclusions Plasmodium falciparum remains the prevalent malaria parasite. Despite low mortality rate, severe malaria is not rare and is a significant predictor of ETF. To reduce the risk for ETF, studies are needed to examine the effectiveness of combination therapy including parenteral artesunate and a parenteral partner drug for severe malaria. The study alerts the possibility of drug-resistant malaria in Africa and other areas in Vietnam, which are known as non-endemic areas of anti-malarial drug resistance. A more comprehensive study using molecular technique in these regions is required to completely understand the magnitude of drug-resistant malaria and to design appropriate control strategies.


2020 ◽  
Vol 6 (1) ◽  
pp. 1
Author(s):  
Boushab Mohamed Boushab ◽  
Mohamed Salem Ould Ahmedou Salem ◽  
Ali Ould Mohamed Salem Boukhary ◽  
Philippe Parola ◽  
Leonardo Basco

Severe malaria in adults is not well-studied in Sahelian Africa. Clinical features and mortality associated with severe Plasmodium falciparum malaria in adult patients hospitalized in Kiffa, southern Mauritania, were analysed. Patients over 15 years old admitted for severe malaria between August 2016 and December 2019 were included in the present retrospective study. The World Health Organization (WHO) criteria were used to define severe malaria. The presenting clinical characteristics and outcome were compared. Of 4266 patients hospitalized during the study period, 573 (13.4%) had a positive rapid diagnostic test for malaria, and 99 (17.3%; mean age, 37.5 years; range 15–79 years; sex-ratio M/F, 2.1) satisfied the criteria for severe malaria. On admission, the following signs and symptoms were observed in more than one-fourth of the patients: fever (98%), impairment of consciousness (81.8%), multiple convulsions (70.7%), cardiovascular collapse (61.6%), respiratory distress (43.4%), severe anaemia ≤ 80 g/L (36.4%), haemoglobinuria (27.3%), and renal failure (25.3%). Patients were treated with parenteral quinine or artemether. Fourteen (14.1%) patients died. Multiple convulsions, respiratory distress, severe anaemia, haemoglobinuria, acute renal failure, jaundice, and abnormal bleeding occurred more frequently (p < 0.05) in deceased patients. Mortality due to severe falciparum malaria is high among adults in southern Mauritania. An adoption of the WHO-recommended first-line treatment for severe malaria, such as parenteral artesunate, is required to lower the mortality rate associated with severe malaria.


Sign in / Sign up

Export Citation Format

Share Document